Last reviewed · How we verify
RDC-0313
At a glance
| Generic name | RDC-0313 |
|---|---|
| Sponsor | Alkermes, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults (PHASE1)
- ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine (PHASE1)
- ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence (PHASE2)
- ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder (PHASE2)
- ALK33-001: A Study of RDC-0313 Administered to Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RDC-0313 CI brief — competitive landscape report
- RDC-0313 updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI